Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240434 | 1.00 | LMNA (0.44) | LMNANPC1RAB9APOLBALDH1A1 | |
| SCHEMBL2240424 | 1.00 | LMNA (0.44) | LMNANPC1RAB9APOLBALDH1A1 | |
| SCHEMBL2240430 | 1.00 | LMNA (0.44) | LMNANPC1RAB9APOLBALDH1A1 | |
| SCHEMBL12355495 | 0.77 | CHRNB2 (0.51) | — | |
| SCHEMBL14053851 | 0.77 | CHRNB2 (0.51) | — | |
| SCHEMBL14054540 | 0.77 | CHRNB2 (0.51) | — | |
| SCHEMBL14053857 | 0.77 | CHRNB2 (0.51) | — | |
| SCHEMBL14054537 | 0.77 | CHRNB2 (0.51) | — | |
| SCHEMBL12349938 | 0.75 | LMNA (0.49) | LMNANPC1RAB9APOLBALDH1A1 | |
| SCHEMBL14053720 | 0.72 | CYP19A1 (0.38) | RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536687-A2 | PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120302756-A1 | PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| WO-2011103263-A2 | PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302756-A1 | PROCESS FOR SYNTHESIS OF 2-SUBSTITUTED PYRROLIDINES AND PIPERADINES | DHPS, ALDH18A1, QDPR | LMNA 3995/4885NPC1 3939/4885RAB9A 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.